# Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

> **NCT00610792** · PHASE2 · WITHDRAWN · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 91 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** bortezomib
- **DRUG:** pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT00610792
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-07
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 91 (ESTIMATED)
- **Why stopped:** Study never submitted to IND. Study is being sponsored by Johnson and Johnson in the EU only.
- **Last updated:** 2009-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610792, "Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00610792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*